We retrospectively examined comorbid conditions and health maintenance in 198 patients aged у55 years who attended 3 New York City human immunodeficiency virus (HIV) clinics between 1 January 1990 and 30 June 1998. Annual influenza and pneumococcal vaccinations within 5 years were given in 82% and 86% of patients, respectively. Among 57 women, 79% had a Papanicolaou smear within 1 year, and 53% had a mammogram within 2 years. Of 165 patients who received care after 1 July 1996, 147 (89%) had comorbid conditions (mean number of conditions, 2.4), and 133 (81%) received HIV-unrelated medications (mean number of medications, 2.7). Receipt of highly active antiretroviral therapy, its discontinuation because of toxicity, and having an undetectable HIV load were not related to comorbid conditions or use of concurrent medications. Comorbid conditions and use of concurrent HIV-unrelated medications need not adversely affect treatment of HIV-infected older individuals, but increased attention to health maintenance may be necessary.
plex medical regimens [10] . Practitioners may be reluctant to prescribe complex combination therapy to their older patients, especially when these patients may have comorbid conditions that require long-term use of additional medications, because the pill burden may be perceived as complicating necessary adherence to a strict medication regimen [11] . HIV-infected individuals у55 years old have nearly 4 times more chronic comorbid conditions than do those !45 years old [12] . As survival from HIV infection improves in response to the availability of more effective therapy, unrelated medical conditions are likely to assume increasing importance as causes of morbidity and mortality in persons with HIV infection. However, poorer prognosis due to more rapid HIV disease progression among older HIV-infected patients may have an impact on practitioner adherence to health maintenance screening guidelines for these individuals [13] .
To determine the characteristics of disease due to HIV infection in older individuals, including comorbid conditions and the use of antiretroviral therapies, we conducted a retrospective review of clinical experience at our institutions. The objectives of this study were (1) to describe the demographic characteristics, HIV risk behaviors, and clinical disorders of older persons with HIV infection who received primary care at 3 inner-city HIV clinics; (2) to assess possible associations of comorbid conditions and treatment for such conditions with receipt of, benefit from, and adverse reactions to antiretroviral therapies; and (3) to determine the level of routine health maintenance not necessarily related to HIV infection received by patients.
METHODS
Outpatient medical records for all HIV-infected patients у55 years old who had у2 clinic visits (у1 visit after the patient reached age 55 years) between 1 , and health maintenance screening (including documentation of mammography within 2 years and annual Papanicolaou smears for women, history of pneumococcal and influenza vaccinations, measurement of serum total cholesterol level, tuberculin skin testing, and mental status evaluation) were abstracted from standardized data-collection forms. If a standardized neurocognitive examination or an evaluation by a neurologist or psychiatrist had been documented, the patient was considered to have had a formal mental status evaluation. A patient was considered to have used antiretroviral or other medications if there was evidence in the medical record that medication was prescribed and no evidence that the patient was not taking it. The 3 clinics each had equivalent policies regarding care of HIV-infected patients, including documentation of health maintenance procedures, neurocognitive assessment, risk behaviors for HIV acquisition, prescription of HIV-related and -unrelated medications, and presence of comorbid conditions. Published guidelines were used for determining adherence to standard practices for health maintenance procedures, vaccinations, and use of PCP prophylaxis [14] [15] [16] . The interval since the health care screening was calculated as the time elapsed between the screening and the most recent recorded visit to the clinic. It was assumed that tests or procedures for which there was no documentation had not been done.
The use and tolerability of HAART, which became available in early 1996, was evaluated in a subgroup consisting of 165 patients who received care at 1 of the 3 clinics after 1 July 1996. US Department of Health and Human Services guidelines for the use of HAART were published in April 1998 [17] . HAART was defined as the combination of nucleoside analogue reversetranscriptase inhibitors (NRTIs) with a nonnucleoside analogue reverse-transcriptase inhibitor, an HIV-1 protease inhibitor (PI), or both.
Categorical data were analyzed by the x 2 test or Fisher's exact test, and continuous data were analyzed by t tests or the nonparametric Kruskal-Wallis test. The study was approved by the institutional review board for the protection of human subjects at each institution.
RESULTS
One hundred ninety-eight HIV-infected patients у55 years of age were seen at 1 of the 3 clinics during the study period. There were no significant differences between patient characteristics at the clinic sites. Fifty-seven patients (29%) were women. The median age of all patients was 59 years (range, 55-82 years). Ninety-eight patients (50%) were non-Hispanic black, and 95 patients (48%) were Hispanic (table 1). Assessment of risk factors for HIV acquisition revealed that the only risk factor was heterosexual contact with a high-risk partner (a person known to be infected with HIV, a commercial sex worker, or, for women, a bisexual man) for 95 patients (47%) and was injection drug use for 59 (30%); 11 patients (6%) were men who had sex with men (MSM) and had no other risk factors; and 19 (10%) had no reported risk factor. Twelve patients (6%) had multiple risk factors. The median CD4 ϩ lymphocyte count at first clinic visit was 239 cells/mm 3 . Sixty-seven percent (132) of the patients had received a diagnosis of AIDS by the most recent clinic visit, and 58% (76) of these had an AIDS-defining clinical condition. The most common AIDSrelated diagnoses were PCP (19% [19] of 99 AIDS-related diagnoses), esophageal candidiasis (16% [16] ), HIV wasting (15% [15] ), HIV dementia (12% [12] ), and cytomegalovirus disease (11% [11] ). No difference in demographic characteristics by sex was found, except that women were more likely to have heterosexual contact as the HIV risk factor (67% [38 of 57] among women vs. 40% [57 of 141] among men;
). P p .001 The proportions of the 198 HIV-infected patients who had documentation of specific health maintenance procedures are shown in table 2. Among women, 53% had a mammogram within 2 years of the most recent clinic visit, and 79% had a Papanicolaou smear within 1 year. The majority of patients had received pneumococcal vaccine within 5 years (86%), annual influenza vaccination (82%), annual tuberculin skin testing when indicated (77%), and serum cholesterol measurement at some time (68%). Formal evaluation of mental status at any time was documented for only 4% of patients. PCP prophylaxis was used when indicated for 96% of patients [15] . There were no differences among racial/ethnic groups in screening for cholesterol, tuberculin skin testing, formal mental status evaluation, provision of pneumococcal or influenza vaccination, performance of mammogram or Papanicolaou smears among women, or use of PCP prophylaxis. When health maintenance procedures among men and among women were compared, the only difference found was that, among eligible patients (excluding those who were allergic, who reported prior vaccination, or who refused vaccination), men (122 of 129) were more likely than women (45 of 53) to have received pneumococcal vaccination ( ). P p .04 For the subgroup of patients who received care after the introduction of HAART, 165 individuals seen after 1 July 1996, the demographic characteristics (age at most recent visit, race/ ethnicity, and sex) were not significantly different from those of the other 33 patients. The median age at time of HIV diagnosis was 54 years (range, 43-75 years), and the median time of clinic follow-up was 29 months (range, 0-116 months). One hundred seven (65%) of these 165 patients had AIDS, and 58 (54%) of those had an AIDS-defining clinical condition. (table 3) . Of the 133 patients with long-term use of HIV-unrelated medications, 112 (84%) also were receiving antiretroviral therapy (including 86 patients taking HAART) at the most recent clinic visit. The median number of concurrent HIV-unrelated medications was 2 (range, 1-6 medications) for patients receiving HAART and 3 (range, 1-9 medications) for those not receiving HAART ( ). P p .6 Thirty-eight (37%) of 104 patients using HAART discontinued antiretroviral therapy on у1 occasion because of toxicity; gastrointestinal intolerance, anemia, and rash were the most common side effects. Thirty-eight percent of patients (24 of 64) receiving у2 concurrent HIV-unrelated medications (the median number) discontinued HAART because of toxicity. The proportion among patients receiving !2 concurrent HIV-unrelated medications did not differ significantly (35%; 14 of 40) (P p ). Likewise, 39% (26 of 67) of patients with у2 comorbid .96 conditions discontinued HAART because of toxicity, which did not differ significantly from the proportion among patients with !2 comorbid conditions (32%; 12 of 37) ( ). P p .66 Among 122 patients for whom HIV-1 load was measured within 4 months of the most recent recorded clinic visit, 101 (83%) were receiving antiretroviral therapy, of whom 81 (80%) received HAART. Forty-two (34%) of the 122 patients had a virus load !400 copies/mL within 4 months of their last visit. The virus load was undetectable in 32 (40%) of the 81 patients who had received HAART, compared with 10 (24%) of the 41 who had not (OR, 2.0; 95% CI, 0.87-4.7;
). P p .1 There was no significant association between a plasma HIV-1 load !400 copies/mL at the most recent measurement and the presence of comorbid conditions or the number of concurrent HIV-unrelated medications. Among 81 patients receiving HAART, 31 (42%) of 74 patients with a comorbid condition and 1 (14%) of 7 patients without a comorbid condition had a virus load !400 copies/mL ( ). Twenty-seven (40%) P p .23 of 68 patients who received у1 concurrent HIV-unrelated medication and 5 (38%) of 13 who received no such medication had virus loads !400 copies/mL ( ). Thirty-six (24%) P p .82 of 153 patients for whom such data were available had documentation of substance abuse. Neither use of HAART nor plasma HIV-1 load !400 copies/mL was significantly associated with substance abuse.
DISCUSSION
It is projected that by the year 2030, the number of individuals age у65 years will double, to 170 million, constituting 20% of the population of the United States [18] . The prevalence of HIV infection likely will increase as older individuals acquire new infections and the use of HAART leads to prolonged survival of individuals who were infected at a younger age. Management of disease in these patients will pose many challenges to our health care system. The results of this study of older HIV-infected individuals demonstrate the importance of heterosexual transmission of HIV, that the presence of comorbid conditions and long-term use of concurrent medications need not preclude the successful use of HAART, and that insufficient attention appears to have been given to cognitive screening.
Heterosexual transmission of HIV is growing in importance among older persons and accounts for 15% of AIDS cases in those 150 years old [2, [19] [20] [21] . However, older persons with HIV risk factors are less likely to have received HIV testing than are young adults [22] . Unsuspected HIV infection was identified (by testing discarded serum) in 5% of patients 160 years old who died in one New York City hospital [23] .
In our study of HIV-infected inner-city residents у55 years old, heterosexual contact with a high-risk partner was identified as the major risk factor for HIV acquisition for almost onehalf (47%) of the subjects, including 40% of male subjects. In comparison with a group of 7489 HIV-infected individuals with AIDS who were 150 years old in the United States in 1996 [2] , our sample of individuals with AIDS ( ) had a higher n p 132 proportion of women (29% in the present study vs. 16% in the larger group), Hispanic individuals (48% vs. 17%), injection drug users (30% vs. 19%), and individuals with risk from unprotected heterosexual behavior (46% vs. 15%) and had fewer white individuals (1% vs. 39%), MSM (7% vs. 36%), and individuals with no identified risk behavior (10% vs. 26%).
More than 80% of patients in our study had documentation of influenza and pneumococcal vaccination. Although it is not strictly comparable in terms of patient characteristics and is dependent on self-reporting, information on general use of these vaccines in New York State in 1997 is available from the Behavioral Risk Factor Surveillance System (BRFSS) [24] [25] [26] .
Statewide, among persons у65 years old, influenza vaccination was reported among 65% and pneumococcal vaccination among 39%, with lower rates for persons of color (those who did not self-identify as white non-Hispanic) [26] . Therefore, the vaccination rates observed among our HIV-infected older patients compare quite favorably with rates reported among older individuals throughout New York State. This observation might reflect more frequent exposure to medical care among HIV-infected persons and heightened awareness of indications for vaccination recommendations by the HIV specialist or the patient. An unexpected finding was that women were less likely to have received pneumococcal vaccination than were men in our study, in contrast with national and statewide data, which did not demonstrate sex differences in this variable [25, 26] . It is important to study this further in HIV-infected persons of similar socioeconomic status.
In contrast, BRFSS data demonstrated that 78% of women in New York State aged у50 years reported having had a mammogram in the previous 2 years, yet only 53% of our sample of women had documentation of mammograms [24, 25] . It may be that less emphasis is placed on conditions unrelated to HIV disease by HIV specialists. This might explain the substantially lower rate of mammography among women in our study, compared with Papanicolaou smear screening, which was documented for 79% of our subjects. Unlike cervical neoplasia, which has been associated with HIV infection [27] , no association between HIV infection and breast cancer has been established. However, it is important for clinicians to realize that HIV infection certainly does not protect against breast cancer, and therefore there is no rationale for relaxing surveillance for this important condition.
Documentation of any formal evaluation of cognitive function in our sample during the study period was rare. HIVassociated dementia has been reported in ∼15% of HIV-infected adult patients, and older age at AIDS diagnosis is a significant risk factor [28, 29] . The impact of HIV-associated cognitive decline on psychosocial interactions, adherence to medications, and ability to benefit from educational intervention can be profound. Serial cognitive and neurologic evaluations have been recommended for the assessment and treatment of the neuropsychiatric aspects of AIDS [30] . Our study does not address the issue of whether lack of testing for cognitive decline reflects provider unawareness of the importance of HIV-associated dementia (formal cognitive function assessment was not required by any of the clinics during the study period) or the difficulty of performing formal tests in a clinic session.
More than one-third of individuals in the United States will have a chronic health-related condition that will affect their normal functioning by age 65 years [31] . Alterations in drug metabolism related to age and comorbid conditions may require dose adjustment or avoidance of certain medications or combinations of medications. The results of this study suggest that antiretroviral use by older patients need not be adversely affected by the presence of chronic comorbid conditions and polypharmacy associated with aging. Our findings indicate that discontinuation of HAART was not associated with concurrent use of other medications. Serious adverse reactions to medication occur more frequently among elderly individuals than among younger adults [18] . However, the proportion (37%) of HIV-infected patients у55 years old in our study who discontinued or modified HAART at least once because of toxicity is similar to that reported for adults of all ages [32] .
Forty percent of the patients in our study who were receiving HAART at the time of their most recent recorded clinic visit had a concurrent plasma HIV-1 load !400 copies/mL. This is similar to reports from general clinical practice for HIV-infected patients of all ages, in which the rate of undetectable plasma HIV-1 load at у6 months after HAART initiation ranges from 37% to 44% [33] [34] [35] . The assumption that older individuals may have more difficulty in achieving success with complex antiretroviral therapy may be challenged by the absence of evidence in the present study that chronic medical conditions and long-term use of the drugs used to treat them were associated with inability to achieve undetectable virus loads.
It is of considerable concern that, after HAART became available, more than one-fourth of patients receiving treatment received suboptimal therapy. It seems possible that, despite the general availability of convincing data supporting its use, routine HAART was withheld by some clinicians at least until official guidelines were published, just 2 months before the end of our study period [17] . It will be important to determine whether prescription of HAART regardless of patient age has improved subsequently with increased familiarity of clinicians with official guidelines and increased experience using antiretroviral therapy.
Incomplete data availability and interobserver and interinstitutional variation in documentation are limitations of a multi-institutional retrospective study. Observer bias was addressed to some extent by collecting data on the basis of strictly defined criteria and using standardized data-collection forms. Sample size was limited, and therefore the power for some analyses was not optimal.
Prospective studies are needed to determine virologic response and the rate and extent of immunologic recovery in older patients with HIV infection who are receiving HAART. Further studies also will be necessary to assess whether and how care delivered to older persons with HIV infection has changed as additional medications have become available and increasing numbers of patients have led to greater expertise on the part of many of the clinicians who provide their care.
